Study S000786

Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05564117
Acronym: OASIS 4
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 307
Start: 2022-10-11
Primary completion: 2024-04-18
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:Semaglutide; DRUG:Placebo semaglutide
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1271-9056; EUDRACT_NUMBER:2021-006534-40

Registered primary outcomes

Percentage Change in Body Weight [Baseline (week 0), end of treatment (week 64)]
Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal to (≥) 5% (Yes/No) [At end of treatment (week 64)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016015	Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton S, The New England journal of medicine	2025	Randomized trial	PMID 40934115 DOI	cites ClinicalTrials.gov:NCT05564117; registry reference DERIVED:40934115